GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064882 | Esophagus | ESCC | dolichol-linked oligosaccharide biosynthetic process | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
GO:00064902 | Esophagus | ESCC | oligosaccharide-lipid intermediate biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
GO:0006488 | Oral cavity | OSCC | dolichol-linked oligosaccharide biosynthetic process | 15/7305 | 18/18723 | 1.53e-04 | 1.07e-03 | 15 |
GO:00091001 | Oral cavity | OSCC | glycoprotein metabolic process | 185/7305 | 387/18723 | 2.37e-04 | 1.54e-03 | 185 |
GO:0006490 | Oral cavity | OSCC | oligosaccharide-lipid intermediate biosynthetic process | 15/7305 | 19/18723 | 4.64e-04 | 2.76e-03 | 15 |
GO:00091011 | Oral cavity | OSCC | glycoprotein biosynthetic process | 151/7305 | 317/18723 | 1.01e-03 | 5.26e-03 | 151 |
GO:00064864 | Oral cavity | OSCC | protein glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00434134 | Oral cavity | OSCC | macromolecule glycosylation | 111/7305 | 226/18723 | 1.22e-03 | 6.10e-03 | 111 |
GO:00700853 | Oral cavity | OSCC | glycosylation | 117/7305 | 240/18723 | 1.29e-03 | 6.42e-03 | 117 |
GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DOLPP1 | SNV | Missense_Mutation | | c.593N>A | p.Pro198His | p.P198H | Q86YN1 | protein_coding | tolerated(0.13) | benign(0.04) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD |
DOLPP1 | SNV | Missense_Mutation | | c.572N>G | p.Phe191Cys | p.F191C | Q86YN1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-E9-A22D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | SD |
DOLPP1 | SNV | Missense_Mutation | novel | c.526N>A | p.Ala176Thr | p.A176T | Q86YN1 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | novel | c.250N>T | p.Arg84Trp | p.R84W | Q86YN1 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | rs745414713 | c.640N>A | p.Val214Ile | p.V214I | Q86YN1 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-BS-A0U8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
DOLPP1 | SNV | Missense_Mutation | rs370550987 | c.433N>A | p.Ala145Thr | p.A145T | Q86YN1 | protein_coding | tolerated(0.76) | benign(0.003) | TCGA-D1-A17M-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | rs770551586 | c.136G>A | p.Gly46Ser | p.G46S | Q86YN1 | protein_coding | tolerated(0.35) | benign(0.028) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | novel | c.280N>T | p.Gly94Cys | p.G94C | Q86YN1 | protein_coding | tolerated(0.18) | benign(0.421) | TCGA-34-2604-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | | c.692G>A | p.Arg231His | p.R231H | Q86YN1 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-BR-8078-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DOLPP1 | SNV | Missense_Mutation | novel | c.448N>T | p.Val150Phe | p.V150F | Q86YN1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |